<DOC>
	<DOCNO>NCT00790010</DOCNO>
	<brief_summary>The purpose research study determine safety use study drug bevacizumab ipilimumab together , dose combination give people safely . This study also seek investigate whether use study drug lengthen amount time participant melanoma worsens .</brief_summary>
	<brief_title>Bevacizumab Plus Ipilimumab Patients With Unresectable Stage III IV Melanoma</brief_title>
	<detailed_description>- There two phase research study , Induction Phase Maintenance Phase . - Induction Phase : Participants receive ipilimumab infusion vein central line week 1 , 4 , 7 10 total 4 infusion . Bevacizumab also give infusion vein central line week 1 , 4 , 7 10 along ipilimumab every 3 week . During cycle study therapy , participant physical exam first day undergo blood test every study visit . At week 1 , 4 , 7 , 10 12 urine sample obtain analysis . - Chest , abdomen pelvic CT scan perform week 12 . If scan week 12 show participant cancer remain stable decrease , ask repeat CT scan three month . - Positron Emission Tomography ( PET ) scan do week 8 week 16 . - Maintenance Phase : If scan perform week 12 show cancer improve stay , participant continue receive bevacizumab every three week undergo CT scan every 3 month . Also , every 3 month participant may eligible receive additional dos ipilimumab addition bevacizumab .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Measurable unresectable Stage III Stage IV melanoma ECOG Performance Status 0 1 4 week great since treatment Must recover acute toxicity associate prior therapy Life expectancy great 12 week 18 year age old Laboratory value outline protocol Negative screening test HIV , active Hepatitis B Hepatitis C Patients receive prior therapy anthracyclines baseline MUGA echo normal ejection fraction CNS metastases Pregnant nursing woman Prior therapy bevacizumab ipilimumab Active infection Autoimmune disease : Patients history inflammatory bowel disease exclude study patient history symptomatic autoimmune disease Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix Any underlying medical condition , principal investigator 's opinion , make administration study drug hazardous obscure interpretation adverse event Any concurrent medical condition require use systemic steroid Inadequately control hypertension Any prior history hypertensive crisis hypertensive encephalopathy NYHA Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Significant know vascular disease Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure significant traumatic injury within 28 day prior study enrollment Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer bone fracture Proteinuria screen Known hypersensitivity component bevacizumab History hemoptysis within 3 month prior study enrollment Current , ongoing treatment fulldose warfarin equivalent Current recent ( within 10 day enrollment ) use aspirin ( &gt; 325mg/day ) chronic use NSAIDs Medications inhibit platelet function Known involvement melanoma within gastrointestinal tract Ulcerated skin lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>ipilimumab</keyword>
	<keyword>unresectable stage III melanoma</keyword>
	<keyword>unresectable stage IV melanoma</keyword>
</DOC>